en.Wedoany.com Reported - InStride Health, a provider of pediatric and adolescent mental health services, has secured $30 million in Series C funding to drive growth, expand into new markets, and broaden its payer partner network.

The round was led by new strategic investors Echo Health Ventures and FMZ Ventures, with participation from existing investors including Valtruis, .406 Ventures, General Catalyst, and Mass General Brigham Ventures.

InStride Health received $30 million in Series B funding in March 2024 and $26 million in 2022. To date, the company has raised a total of $86 million.

Founded in 2021, InStride Health provides insurance-based virtual specialty care for children, adolescents, and young adults with anxiety disorders and obsessive-compulsive disorder (OCD). The company was co-founded by Harvard-trained clinicians from McLean Hospital, along with healthcare and technology leaders. Mona Potter, M.D., and Kathryn Boger, Ph.D., jointly developed the McLean Anxiety Mastery Program (MAMP) at McLean Hospital. They decided to scale the model that worked well in an academic hospital setting, offering broader, more flexible mental health treatment covered by insurance. They partnered with healthcare entrepreneur John Voith, who spent nearly seven years at athenahealth leading interoperability initiatives before co-founding the teledentistry company Virtudent.

McLean's pediatric mental health model achieved significant results, but many families could not access services due to a lack of insurance coverage and long waiting lists. CEO Voith stated that the program was limited to 10 to 15 patients at a time and was a self-pay program, whereas the company aims to provide greater accessibility and scale this quality of care nationwide.

InStride Health continues to expand its reach with a clinically driven, technology-enabled approach, delivering evidence-based treatment for individuals aged 7 to 24 with complex anxiety disorders, OCD, and related conditions. Each patient is assigned a dedicated care team consisting of a psychiatrist, therapist, and exposure coach, providing real-time support through daily tools such as text messaging and a mobile app supporting video and chat, guiding patients through personalized programs with clear milestones and real-world exposure exercises. The care team can also coordinate with the patient's support network outside of sessions, including parents, family members, school staff, and existing providers.

The company's published clinical data shows that 97% of pediatric patients with anxiety disorders or OCD demonstrated clinical improvement. The analysis, based on 3,604 care episodes from 2023 to 2025, showed an average 53% reduction in anxiety scores, 81% of caregivers reported reduced stress, and less than 1% of patients required hospitalization within 12 months of treatment. Two-thirds of patients (66%) were referred to the program through health plans or providers, and 98% of caregivers would recommend InStride Health's services to a friend. In 2025, the company's care team grew by 90%, and the number of patients treated doubled, while clinical outcomes remained consistent.

InStride Health's services are available in 17 states, primarily on the East Coast and in Texas, compared to just 8 states in 2024. The company has treated 5,000 patients. The new funding will support the company's expansion in key growth markets, including Massachusetts, New York, Pennsylvania, New Jersey, and Texas, and broaden its footprint in the Midwest and West. The company plans to initiate expansion within the next 12 months.

Partnering with payers to provide insurance-based services is a key differentiator for InStride Health, which has established in-network collaborations with most major commercial insurers, including Aetna, Anthem, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Oscar.

Echo Health Ventures is the strategic corporate venture capital arm of the Blue Cross Blue Shield plan collaborative network, and FMZ Ventures is a growth equity firm investing in companies in the experience economy and digital consumer markets.

Voith noted that this funding round reflects investor confidence in InStride's model, which combines pediatric mental health expertise with technology and artificial intelligence infrastructure. The company integrates clinical excellence with domain-specific AI, supporting clinical excellence through workflow tools and clinical decision support tools, while allowing the care team to remain responsible for diagnosis, care planning, and maintaining direct relationships with patients.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com